Bayer's Xofigo carves out niche

Bayer's Xofigo carves out niche
Bayer's Xofigo carves out niche

Bayer's cancer drug Xofigo is already a revenue driver for manufacturer Bayer. The company announced that the drug, approved for castration-resistant metastatic prostate cancer, earned $57 million during the quarter, and cited the drug as one of the quarter's key sales drivers along with newish blood thinner Xarelto and wet age-related macular degeneration drug Eylea.

Consultancy Decision Resources is also taking note, reporting Wednesday that over two-thirds of surveyed oncologists have prescribed the drug since its May 2013 approval and that a significant chunk of doctors who said they had yet to prescribe the treatment indicated that they expect to by the year's end.

Decision Resources says about a third of prescribing doctors are using the alpha-emitting radiopharmaceutical along with other drugs including Janssen's Zytiga (aberacitone acetate) and AbbVie's Lupron (leuprolide acetate).

Decision Resources Group Analyst Jennifer Bamford said in a statement that the drug is tripping over some basics, such as providers not being familiar with it. She also said doctors find the need for a nuclear medicine facility off-putting.

Bayer's expectations for the drug indicate the company considers these as minor points—the drugmaker estimated last year that the cancer medication could reach $1.31 billion in annual sales.

You must be a registered member of MMM to post a comment.

Next Article in Channel


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.